| 1232 | Humans (MeSH) |
| 939 | Animals (MeSH) |
| 687 | Sirolimus (pharmacology) |
| 520 | Saccharomyces cerevisiae Proteins (metabolism) |
| 505 | Signal Transduction (MeSH) |
| 495 | Mice (MeSH) |
| 488 | Saccharomyces cerevisiae (metabolism) |
| 485 | Saccharomyces cerevisiae (genetics) |
| 470 | TOR Serine-Threonine Kinases (metabolism) |
| 380 | Saccharomyces cerevisiae Proteins (genetics) |
| 372 | Female (MeSH) |
| 354 | Male (MeSH) |
| 258 | Phosphorylation (MeSH) |
| 227 | Transcription Factors (metabolism) |
| 222 | Signal Transduction (drug effects) |
| 219 | Saccharomyces cerevisiae (drug effects) |
| 217 | Gene Expression Regulation, Fungal (MeSH) |
| 196 | Protein-Serine-Threonine Kinases (metabolism) |
| 196 | Cell Line, Tumor (MeSH) |
| 194 | Cell Line (MeSH) |
| 189 | Mechanistic Target of Rapamycin Complex 1 (MeSH) |
| 188 | Mutation (MeSH) |
| 185 | Phosphatidylinositol 3-Kinases (metabolism) |
| 182 | TOR Serine-Threonine Kinases (genetics) |
| 177 | Middle Aged (MeSH) |
| 177 | Mice, Inbred C57BL (MeSH) |
| 175 | Multiprotein Complexes (metabolism) |
| 175 | Cells, Cultured (MeSH) |
| 169 | Adult (MeSH) |
| 162 | TOR Serine-Threonine Kinases (antagonists & inhibitors) |
| 161 | Autophagy (MeSH) |
| 160 | Molecular Sequence Data (MeSH) |
| 160 | Amino Acid Sequence (MeSH) |
| 159 | Autophagy (drug effects) |
| 143 | Transcription Factors (genetics) |
| 142 | Antifungal Agents (pharmacology) |
| 137 | Models, Biological (MeSH) |
| 137 | Fungal Proteins (metabolism) |
| 135 | Signal Transduction (physiology) |
| 134 | Protein Kinases (metabolism) |
| 132 | Proto-Oncogene Proteins c-akt (metabolism) |
| 129 | TOR Serine-Threonine Kinases (MeSH) |
| 129 | Saccharomyces cerevisiae (enzymology) |
| 127 | Sirolimus (therapeutic use) |
| 127 | Immunosuppressive Agents (therapeutic use) |
| 123 | Protein Binding (MeSH) |
| 122 | Immunosuppressive Agents (pharmacology) |
| 118 | Fungal Proteins (genetics) |
| 116 | Nitrogen (metabolism) |
| 116 | Mechanistic Target of Rapamycin Complex 1 (metabolism) |
| 115 | Saccharomyces cerevisiae (growth & development) |
| 113 | Saccharomyces cerevisiae (cytology) |
| 107 | Signal Transduction (genetics) |
| 106 | Carrier Proteins (metabolism) |
| 103 | Saccharomyces cerevisiae (physiology) |
| 101 | Time Factors (MeSH) |
| 100 | Cell Proliferation (drug effects) |
| 99 | Protein-Serine-Threonine Kinases (genetics) |
| 95 | Disease Models, Animal (MeSH) |
| 91 | Gene Deletion (MeSH) |
| 90 | Aged (MeSH) |
| 89 | Phosphatidylinositol 3-Kinases (genetics) |
| 89 | Mice, Knockout (MeSH) |
| 87 | Blotting, Western (MeSH) |
| 86 | DNA-Binding Proteins (metabolism) |
| 85 | Saccharomyces cerevisiae Proteins (MeSH) |
| 84 | Transcription, Genetic (MeSH) |
| 79 | Multiprotein Complexes (genetics) |
| 78 | Sirolimus (MeSH) |
| 78 | Autophagy (physiology) |
| 78 | Apoptosis (drug effects) |
| 76 | Phosphorylation (drug effects) |
| 75 | Mitochondria (metabolism) |
| 75 | Immunosuppressive Agents (adverse effects) |
| 75 | Adaptor Proteins, Signal Transducing (metabolism) |
| 73 | Phosphotransferases (Alcohol Group Acceptor) (metabolism) |
| 73 | Mice, Inbred BALB C (MeSH) |
| 73 | Base Sequence (MeSH) |
| 72 | Cell Cycle Proteins (metabolism) |
| 71 | Sirolimus (metabolism) |
| 70 | Saccharomyces cerevisiae Proteins (physiology) |
| 69 | Saccharomyces cerevisiae Proteins (chemistry) |
| 69 | Phenotype (MeSH) |
| 69 | Cell Proliferation (MeSH) |
| 69 | Carrier Proteins (genetics) |
| 68 | Genes, Fungal (MeSH) |
| 68 | Gene Expression Regulation, Fungal (drug effects) |
| 67 | Protein Kinases (genetics) |
| 66 | Virus Replication (MeSH) |
| 64 | Kidney Transplantation (adverse effects) |
| 64 | Cell Nucleus (metabolism) |
| 63 | Gene Expression Profiling (MeSH) |
| 63 | Autophagy (genetics) |
| 62 | Protein Biosynthesis (MeSH) |
| 62 | Phosphoproteins (metabolism) |
| 61 | Gene Expression Regulation (MeSH) |
| 60 | Schizosaccharomyces pombe Proteins (metabolism) |
| 60 | Reactive Oxygen Species (metabolism) |
| 60 | Host-Pathogen Interactions (MeSH) |
| 60 | Amino Acids (metabolism) |
| 59 | Treatment Outcome (MeSH) |
| 59 | RNA, Messenger (metabolism) |
| 59 | Protein Kinase Inhibitors (pharmacology) |
| 58 | Antineoplastic Agents (pharmacology) |
| 57 | Tacrolimus (pharmacology) |
| 57 | Schizosaccharomyces (genetics) |
| 57 | RNA, Messenger (genetics) |
| 56 | Sirolimus (administration & dosage) |
| 56 | Repressor Proteins (metabolism) |
| 56 | Mechanistic Target of Rapamycin Complex 2 (MeSH) |
| 55 | Membrane Proteins (metabolism) |
| 55 | Mechanistic Target of Rapamycin Complex 1 (genetics) |
| 55 | Intracellular Signaling Peptides and Proteins (metabolism) |
| 54 | Saccharomyces cerevisiae Proteins (antagonists & inhibitors) |
| 54 | Protein Transport (MeSH) |
| 54 | Glucose (metabolism) |
| 54 | Flow Cytometry (MeSH) |
| 53 | Virus Replication (drug effects) |
| 52 | Risk Factors (MeSH) |
| 51 | Rats (MeSH) |
| 51 | Phosphoinositide-3 Kinase Inhibitors (MeSH) |
| 51 | Mechanistic Target of Rapamycin Complex 2 (metabolism) |
| 51 | Cell Membrane (metabolism) |
| 50 | Schizosaccharomyces (metabolism) |
| 50 | Cell Survival (drug effects) |
| 49 | Stress, Physiological (MeSH) |
| 49 | Ribosomal Protein S6 Kinases, 70-kDa (metabolism) |
| 49 | Polyenes (pharmacology) |
| 49 | Phosphatidylinositol 3-Kinases (MeSH) |
| 49 | HeLa Cells (MeSH) |
| 49 | Enzyme Activation (MeSH) |
| 49 | Cell Cycle Proteins (MeSH) |
| 48 | Kidney Transplantation (MeSH) |
| 48 | HEK293 Cells (MeSH) |
| 47 | Vacuoles (metabolism) |
| 47 | Tacrolimus Binding Proteins (MeSH) |
| 47 | Sequence Homology, Amino Acid (MeSH) |
| 47 | Retrospective Studies (MeSH) |
| 46 | Microtubule-Associated Proteins (metabolism) |
| 46 | Macrophages (microbiology) |
| 46 | Gene Expression (MeSH) |
| 46 | Cyclic AMP-Dependent Protein Kinases (metabolism) |
| 45 | Sirolimus (adverse effects) |
| 45 | Phosphotransferases (Alcohol Group Acceptor) (genetics) |
| 45 | Mutation (genetics) |
| 45 | Cell Cycle Proteins (genetics) |
| 45 | AMP-Activated Protein Kinases (metabolism) |
| 44 | Signal Transduction (immunology) |
| 44 | Schizosaccharomyces pombe Proteins (genetics) |
| 44 | Enzyme Inhibitors (pharmacology) |
| 43 | Sirolimus (analogs & derivatives) |
| 43 | Mice, Transgenic (MeSH) |
| 43 | Lysosomes (metabolism) |
| 43 | DNA-Binding Proteins (genetics) |
| 43 | Antibiotics, Antineoplastic (pharmacology) |
| 42 | RNA Interference (MeSH) |
| 42 | Proto-Oncogene Proteins c-akt (genetics) |
| 42 | Dose-Response Relationship, Drug (MeSH) |
| 42 | Adaptor Proteins, Signal Transducing (genetics) |
| 41 | Cell Survival (MeSH) |
| 40 | Macrophages (metabolism) |
| 40 | Apoptosis (MeSH) |
| 39 | Xenograft Model Antitumor Assays (MeSH) |
| 39 | Protein-Serine-Threonine Kinases (MeSH) |
| 39 | Protein Structure, Tertiary (MeSH) |
| 39 | Promoter Regions, Genetic (MeSH) |
| 39 | Phagosomes (metabolism) |
| 39 | Microscopy, Fluorescence (MeSH) |
| 38 | Transcription, Genetic (drug effects) |
| 38 | TOR Serine-Threonine Kinases (physiology) |
| 38 | TOR Serine-Threonine Kinases (immunology) |
| 38 | Saccharomyces cerevisiae (MeSH) |
| 38 | Phosphoprotein Phosphatases (metabolism) |
| 38 | Multiprotein Complexes (MeSH) |
| 38 | Immunosuppressive Agents (administration & dosage) |
| 37 | Young Adult (MeSH) |
| 37 | T-Lymphocytes (immunology) |
| 37 | Recombinant Fusion Proteins (metabolism) |
| 37 | Down-Regulation (MeSH) |
| 37 | Adolescent (MeSH) |
| 36 | Transfection (MeSH) |
| 36 | Ribosomes (metabolism) |
| 36 | Drug Therapy, Combination (MeSH) |
| 36 | Cytoplasm (metabolism) |
| 36 | Cytokines (metabolism) |
| 35 | Models, Molecular (MeSH) |
| 35 | Membrane Proteins (genetics) |
| 35 | Cyclosporine (pharmacology) |
| 35 | CD8-Positive T-Lymphocytes (immunology) |
| 35 | Adaptor Proteins, Signal Transducing (MeSH) |
| 34 | Sequence Alignment (MeSH) |
| 34 | Monomeric GTP-Binding Proteins (metabolism) |
| 34 | Monomeric GTP-Binding Proteins (genetics) |
| 34 | Heat-Shock Proteins (metabolism) |
| 34 | Graft Rejection (prevention & control) |
| 34 | Cloning, Molecular (MeSH) |
| 33 | T-Lymphocytes, Regulatory (immunology) |
| 32 | Viral Load (MeSH) |
| 32 | Oxidative Stress (MeSH) |
| 32 | Oligonucleotide Array Sequence Analysis (MeSH) |
| 31 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 31 | Repressor Proteins (genetics) |
| 31 | Protein Phosphatase 2 (metabolism) |
| 31 | Immunocompromised Host (MeSH) |
| 30 | Trans-Activators (metabolism) |
| 30 | Recombinant Fusion Proteins (genetics) |
| 30 | Polymerase Chain Reaction (MeSH) |
| 30 | Phosphatidylinositol 3-Kinases (physiology) |
| 30 | Mice, Nude (MeSH) |
| 30 | Lymphocyte Activation (MeSH) |
| 30 | Immunoblotting (MeSH) |
| 30 | Graft Rejection (immunology) |
| 30 | Gene Expression Regulation, Neoplastic (MeSH) |
| 30 | Binding Sites (MeSH) |
| 29 | Macrophages (immunology) |
| 29 | Intracellular Signaling Peptides and Proteins (genetics) |
| 29 | Cell Differentiation (MeSH) |
| 29 | Antiviral Agents (therapeutic use) |
| 29 | Anti-Bacterial Agents (pharmacology) |
| 28 | Transcription Factors (physiology) |
| 28 | Mechanistic Target of Rapamycin Complex 2 (genetics) |
| 28 | Homeostasis (MeSH) |
| 28 | Glutamine (metabolism) |
| 28 | Enzyme Activation (drug effects) |
| 28 | Candida albicans (genetics) |
| 27 | Transcription Factors (antagonists & inhibitors) |
| 27 | Nuclear Proteins (metabolism) |
| 27 | Mitogen-Activated Protein Kinases (metabolism) |
| 27 | Microtubule-Associated Proteins (genetics) |
| 27 | Microbial Sensitivity Tests (MeSH) |
| 27 | Intracellular Signaling Peptides and Proteins (MeSH) |
| 27 | Green Fluorescent Proteins (metabolism) |
| 27 | Genotype (MeSH) |
| 27 | Gene Expression Regulation (drug effects) |
| 26 | Up-Regulation (MeSH) |
| 26 | Temperature (MeSH) |
| 26 | Sirolimus (chemistry) |
| 26 | Schizosaccharomyces (enzymology) |
| 26 | Ribosomal Proteins (genetics) |
| 26 | Real-Time Polymerase Chain Reaction (MeSH) |
| 26 | Protein-Serine-Threonine Kinases (physiology) |
| 26 | Mitochondria (drug effects) |
| 26 | Immunohistochemistry (MeSH) |
| 26 | Glycogen Synthase Kinase 3 (metabolism) |
| 26 | Gene Knockdown Techniques (MeSH) |
| 26 | Follow-Up Studies (MeSH) |
| 26 | Everolimus (MeSH) |
| 26 | Drug Synergism (MeSH) |
| 26 | Disease Progression (MeSH) |
| 26 | Child (MeSH) |
| 25 | Tumor Cells, Cultured (MeSH) |
| 25 | T-Lymphocytes (metabolism) |
| 25 | Sarcoma, Kaposi (virology) |
| 25 | Proto-Oncogene Proteins c-akt (antagonists & inhibitors) |
| 25 | Proteins (metabolism) |
| 25 | Protein-Serine-Threonine Kinases (antagonists & inhibitors) |
| 25 | Prospective Studies (MeSH) |
| 25 | Polyomavirus Infections (virology) |
| 25 | Phosphoprotein Phosphatases (genetics) |
| 25 | Mechanistic Target of Rapamycin Complex 1 (antagonists & inhibitors) |
| 25 | Immunoprecipitation (MeSH) |
| 25 | Gene Knockout Techniques (MeSH) |
| 25 | Fungal Proteins (chemistry) |
| 25 | Enzyme-Linked Immunosorbent Assay (MeSH) |
| 25 | Cytomegalovirus Infections (virology) |
| 25 | Cell Wall (metabolism) |
| 25 | Carrier Proteins (chemistry) |
| 25 | Candida albicans (drug effects) |
| 25 | Caloric Restriction (MeSH) |
| 25 | Antineoplastic Agents (therapeutic use) |
| 25 | Amino Acid Transport Systems (metabolism) |
| 25 | Adenine (analogs & derivatives) |
| 24 | Yeasts (metabolism) |
| 24 | Protein Processing, Post-Translational (MeSH) |
| 24 | Protein Kinases (physiology) |
| 24 | Morpholines (pharmacology) |
| 24 | Macrophages (drug effects) |
| 24 | Immunity, Innate (MeSH) |
| 24 | Fibroblasts (virology) |
| 24 | Cell Differentiation (drug effects) |
| 24 | Bacterial Proteins (metabolism) |
| 24 | Autophagy-Related Proteins (MeSH) |
| 23 | Yeasts (genetics) |
| 23 | Proteomics (MeSH) |
| 23 | Multiprotein Complexes (antagonists & inhibitors) |
| 23 | Kinetics (MeSH) |
| 23 | Forkhead Transcription Factors (metabolism) |
| 23 | DNA Damage (MeSH) |
| 23 | Conserved Sequence (MeSH) |
| 23 | Cell Cycle (MeSH) |
| 23 | CD4-Positive T-Lymphocytes (immunology) |
| 23 | Autophagosomes (metabolism) |
| 23 | Actins (metabolism) |
| 22 | Virulence (MeSH) |
| 22 | Tumor Suppressor Proteins (metabolism) |
| 22 | Tacrolimus Binding Protein 1A (metabolism) |
| 22 | Tacrolimus (therapeutic use) |
| 22 | Swine (MeSH) |
| 22 | Protein Transport (drug effects) |
| 22 | Prognosis (MeSH) |
| 22 | Graft Survival (drug effects) |
| 22 | Endoplasmic Reticulum (metabolism) |
| 22 | Drug Resistance, Fungal (genetics) |
| 22 | Drug Resistance, Fungal (MeSH) |
| 22 | B-Lymphocytes (immunology) |
| 22 | Alleles (MeSH) |
| 22 | Adenine (pharmacology) |
| 21 | Transcriptome (MeSH) |
| 21 | Structure-Activity Relationship (MeSH) |
| 21 | RNA-Binding Proteins (metabolism) |
| 21 | Protein Phosphatase 2 (genetics) |
| 21 | Protein Phosphatase 2 (MeSH) |
| 21 | Protein Biosynthesis (drug effects) |
| 21 | NF-kappa B (metabolism) |
| 21 | Immunosuppression (MeSH) |
| 21 | GATA Transcription Factors (metabolism) |
| 21 | Everolimus (therapeutic use) |
| 21 | Down-Regulation (drug effects) |
| 21 | Cyclic AMP-Dependent Protein Kinases (genetics) |
| 21 | Candida albicans (metabolism) |
| 21 | Autophagy (immunology) |
| 21 | Aged, 80 and over (MeSH) |
| 20 | Transcriptional Activation (MeSH) |
| 20 | Tacrolimus (metabolism) |
| 20 | T-Lymphocytes (drug effects) |
| 20 | Streptomyces (metabolism) |
| 20 | Schizosaccharomyces (growth & development) |
| 20 | Schizosaccharomyces (cytology) |
| 20 | Ribosomal Proteins (metabolism) |
| 20 | Postoperative Complications (virology) |
| 20 | Polyenes (metabolism) |
| 20 | Lymphocyte Activation (immunology) |
| 20 | Kidney Transplantation (immunology) |
| 20 | Gene Expression Regulation, Fungal (physiology) |
| 20 | Fungal Proteins (physiology) |
| 20 | Fibroblasts (metabolism) |
| 20 | DNA, Fungal (genetics) |
| 20 | Culture Media (MeSH) |
| 20 | Cell Differentiation (immunology) |
| 20 | Carbon (metabolism) |
| 20 | Breast Neoplasms (pathology) |
| 20 | Biological Transport (MeSH) |
| 19 | ras Proteins (metabolism) |
| 19 | Two-Hybrid System Techniques (MeSH) |
| 19 | Tumor Virus Infections (virology) |
| 19 | Tumor Suppressor Proteins (genetics) |
| 19 | Sequence Analysis, DNA (MeSH) |
| 19 | Schizosaccharomyces (drug effects) |
| 19 | Saccharomyces cerevisiae (chemistry) |
| 19 | Reproducibility of Results (MeSH) |
| 19 | RNA, Small Interfering (metabolism) |
| 19 | Protein Conformation (MeSH) |
| 19 | Protein Binding (drug effects) |
| 19 | Phosphatidylinositol 3-Kinases (chemistry) |
| 19 | Neoplasms (drug therapy) |
| 19 | Models, Genetic (MeSH) |
| 19 | MicroRNAs (genetics) |
| 19 | Mice, SCID (MeSH) |
| 19 | Incidence (MeSH) |
| 19 | Immunosuppression (methods) |
| 19 | Graft Survival (MeSH) |
| 19 | Genome, Fungal (MeSH) |
| 19 | Epithelial Cells (virology) |
| 19 | Dendritic Cells (immunology) |
| 19 | Chromones (pharmacology) |
| 19 | Chlorocebus aethiops (MeSH) |
| 19 | Cell Proliferation (genetics) |
| 19 | Cell Division (MeSH) |
| 19 | Cell Cycle (genetics) |
| 19 | Cell Cycle (drug effects) |
| 18 | Wortmannin (MeSH) |
| 18 | Sphingolipids (metabolism) |
| 18 | Species Specificity (MeSH) |
| 18 | Rats, Sprague-Dawley (MeSH) |
| 18 | RNA, Small Interfering (genetics) |
| 18 | RNA, Fungal (genetics) |
| 18 | Phosphotransferases (Alcohol Group Acceptor) (physiology) |
| 18 | Peptidylprolyl Isomerase (metabolism) |
| 18 | Peptidylprolyl Isomerase (MeSH) |
| 18 | Neoplasms (pathology) |
| 18 | Mycophenolic Acid (therapeutic use) |
| 18 | Molecular Structure (MeSH) |
| 18 | MAP Kinase Signaling System (MeSH) |
| 18 | Hyphae (growth & development) |
| 18 | Histones (metabolism) |
| 18 | Genes, Reporter (MeSH) |
| 18 | Gene Regulatory Networks (MeSH) |
| 18 | Gene Expression Regulation, Fungal (genetics) |
| 18 | Epstein-Barr Virus Infections (virology) |
| 18 | Endosomes (metabolism) |
| 18 | Candida albicans (growth & development) |
| 18 | Calcineurin (metabolism) |
| 18 | Breast Neoplasms (metabolism) |
| 18 | Blotting, Northern (MeSH) |
| 18 | Androstadienes (pharmacology) |
| 17 | Vesicular Transport Proteins (metabolism) |
| 17 | Transplantation, Homologous (MeSH) |
| 17 | T-Lymphocytes, Regulatory (drug effects) |
| 17 | Substrate Specificity (MeSH) |
| 17 | RNA-Binding Proteins (genetics) |
| 17 | RNA, Small Interfering (MeSH) |
| 17 | Phosphatidylinositol 3-Kinase (metabolism) |
| 17 | PTEN Phosphohydrolase (metabolism) |
| 17 | Mutagenesis, Site-Directed (MeSH) |
| 17 | Macrophages (cytology) |
| 17 | Lymphocyte Activation (drug effects) |
| 17 | Liver (metabolism) |
| 17 | Ligands (MeSH) |
| 17 | Infant (MeSH) |
| 17 | Hepatocytes (metabolism) |
| 17 | Hep G2 Cells (MeSH) |
| 17 | HIV Infections (virology) |
| 17 | Gene Silencing (MeSH) |
| 17 | Gene Expression (drug effects) |
| 17 | Forkhead Transcription Factors (genetics) |
| 17 | Fermentation (MeSH) |
| 17 | Energy Metabolism (MeSH) |
| 17 | Child, Preschool (MeSH) |
| 17 | Cell Membrane (drug effects) |
| 17 | Caffeine (pharmacology) |
| 17 | Antiviral Agents (pharmacology) |
| 17 | Active Transport, Cell Nucleus (MeSH) |
| 16 | Yeasts (physiology) |
| 16 | Tuberous Sclerosis Complex 2 Protein (MeSH) |
| 16 | Transcription Factors (MeSH) |
| 16 | Trans-Activators (genetics) |
| 16 | Survival Analysis (MeSH) |
| 16 | Stress, Physiological (genetics) |
| 16 | Schizosaccharomyces (physiology) |
| 16 | Proteins (genetics) |
| 16 | Protein Kinases (chemistry) |
| 16 | Promoter Regions, Genetic (genetics) |
| 16 | Plasmids (metabolism) |
| 16 | Phylogeny (MeSH) |
| 16 | Phagosomes (drug effects) |
| 16 | Nuclear Proteins (genetics) |
| 16 | Neoplasms (genetics) |
| 16 | Mycophenolic Acid (analogs & derivatives) |
| 16 | Mutagenesis (MeSH) |
| 16 | Molecular Targeted Therapy (MeSH) |
| 16 | Microscopy, Electron, Transmission (MeSH) |
| 16 | Liver Transplantation (MeSH) |
| 16 | Liver Neoplasms (pathology) |
| 16 | Kidney Failure, Chronic (surgery) |
| 16 | Kidney Diseases (virology) |
| 16 | Intracellular Membranes (metabolism) |
| 16 | Inflammation (metabolism) |
| 16 | Inflammation (immunology) |
| 16 | HIV Infections (drug therapy) |
| 16 | Golgi Apparatus (metabolism) |
| 16 | Genes, Fungal (genetics) |
| 16 | Epithelial Cells (metabolism) |
| 16 | Drug Interactions (MeSH) |
| 16 | DNA Primers (MeSH) |
| 16 | Cytokines (immunology) |
| 16 | Chromatin (metabolism) |
| 16 | Carcinoma, Hepatocellular (pathology) |
| 16 | Calcineurin Inhibitors (MeSH) |
| 16 | Beclin-1 (MeSH) |
| 16 | Autophagy-Related Proteins (metabolism) |
| 16 | AMP-Activated Protein Kinases (genetics) |
| 15 | Viral Proteins (metabolism) |
| 15 | Ubiquitination (MeSH) |
| 15 | Tacrolimus Binding Protein 1A (genetics) |
| 15 | T-Lymphocytes, Regulatory (metabolism) |
| 15 | T-Lymphocytes (virology) |
| 15 | Survival Rate (MeSH) |
| 15 | Ribosomal Protein S6 Kinases (metabolism) |
| 15 | Recombinant Proteins (metabolism) |
| 15 | Rabbits (MeSH) |
| 15 | RNA, Fungal (metabolism) |
| 15 | Proteolysis (MeSH) |
| 15 | Protein Subunits (metabolism) |
| 15 | Phosphoproteins (genetics) |
| 15 | Monocytes (metabolism) |
| 15 | Microbial Viability (MeSH) |
| 15 | MCF-7 Cells (MeSH) |
| 15 | Lymphoproliferative Disorders (virology) |
| 15 | Longevity (drug effects) |
| 15 | Liver Transplantation (adverse effects) |
| 15 | Liver Neoplasms (metabolism) |
| 15 | Hepacivirus (drug effects) |
| 15 | HIV Infections (immunology) |
| 15 | Graft Survival (immunology) |
| 15 | Evolution, Molecular (MeSH) |
| 15 | Everolimus (pharmacology) |
| 15 | Eukaryotic Initiation Factor-4E (metabolism) |
| 15 | Drug Resistance, Neoplasm (drug effects) |
| 15 | Drug Resistance, Neoplasm (MeSH) |
| 15 | Cytokines (genetics) |
| 15 | Cell Movement (drug effects) |
| 15 | Cell Division (drug effects) |
| 15 | Cell Cycle (physiology) |
| 15 | Calcium (metabolism) |
| 15 | Apoptosis Regulatory Proteins (metabolism) |
| 15 | Apoptosis (genetics) |
| 14 | Virus Activation (drug effects) |
| 14 | Vacuoles (drug effects) |
| 14 | Up-Regulation (drug effects) |
| 14 | Tissue Donors (MeSH) |
